Literature DB >> 20226988

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension.

Peter M Rothwell1, Sally C Howard, Eamon Dolan, Eoin O'Brien, Joanna E Dobson, Bjorn Dahlöf, Peter S Sever, Neil R Poulter.   

Abstract

BACKGROUND: The mechanisms by which hypertension causes vascular events are unclear. Guidelines for diagnosis and treatment focus only on underlying mean blood pressure. We aimed to reliably establish the prognostic significance of visit-to-visit variability in blood pressure, maximum blood pressure reached, untreated episodic hypertension, and residual variability in treated patients.
METHODS: We determined the risk of stroke in relation to visit-to-visit variability in blood pressure (expressed as standard deviation [SD] and parameters independent of mean blood pressure) and maximum blood pressure in patients with previous transient ischaemic attack (TIA; UK-TIA trial and three validation cohorts) and in patients with treated hypertension (Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm [ASCOT-BPLA]). In ASCOT-BPLA, 24-h ambulatory blood-pressure monitoring (ABPM) was also studied.
FINDINGS: In each TIA cohort, visit-to-visit variability in systolic blood pressure (SBP) was a strong predictor of subsequent stroke (eg, top-decile hazard ratio [HR] for SD SBP over seven visits in UK-TIA trial: 6.22, 95% CI 4.16-9.29, p<0.0001), independent of mean SBP, but dependent on precision of measurement (top-decile HR over ten visits: 12.08, 7.40-19.72, p<0.0001). Maximum SBP reached was also a strong predictor of stroke (HR for top-decile over seven visits: 15.01, 6.56-34.38, p<0.0001, after adjustment for mean SBP). In ASCOT-BPLA, residual visit-to-visit variability in SBP on treatment was also a strong predictor of stroke and coronary events (eg, top-decile HR for stroke: 3.25, 2.32-4.54, p<0.0001), independent of mean SBP in clinic or on ABPM. Variability on ABPM was a weaker predictor, but all measures of variability were most predictive in younger patients and at lower (<median) values of mean SBP in every cohort.
INTERPRETATION: Visit-to-visit variability in SBP and maximum SBP are strong predictors of stroke, independent of mean SBP. Increased residual variability in SBP in patients with treated hypertension is associated with a high risk of vascular events. FUNDING: None. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226988     DOI: 10.1016/S0140-6736(10)60308-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  485 in total

Review 1.  Hypertension in 2010: new challenges in blood pressure goals and assessment.

Authors:  Suzanne Oparil
Journal:  Nat Rev Cardiol       Date:  2011-02       Impact factor: 32.419

Review 2.  Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).

Authors:  Marissa N Lassere; Kent R Johnson; Michal Schiff; David Rees
Journal:  BMC Med Res Methodol       Date:  2012-03-12       Impact factor: 4.615

Review 3.  Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Authors:  Joseph L Izzo
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

4.  Presence of baseline prehypertension and risk of incident stroke: a meta-analysis.

Authors:  M Lee; J L Saver; B Chang; K-H Chang; Q Hao; B Ovbiagele
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

Review 5.  Mechanisms of vascular damage in obstructive sleep apnea.

Authors:  Malcolm Kohler; John R Stradling
Journal:  Nat Rev Cardiol       Date:  2010-12       Impact factor: 32.419

6.  Adult hypertension is associated with blood pressure variability in childhood in blacks and whites: the bogalusa heart study.

Authors:  Wei Chen; Sathanur R Srinivasan; Litao Ruan; Hao Mei; Gerald S Berenson
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

7.  Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients.

Authors:  Francesca Mallamaci; Giovanni Tripepi; Graziella D'Arrigo; Silvio Borrelli; Carlo Garofalo; Giovanna Stanzione; Michele Provenzano; Luca De Nicola; Giuseppe Conte; Roberto Minutolo; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-02       Impact factor: 8.237

Review 8.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

Review 9.  Labile hypertension: a new disease or a variability phenomenon?

Authors:  Elias Sanidas; Charalampos Grassos; Dimitrios P Papadopoulos; Maria Velliou; Kostas Tsioufis; Marina Mantzourani; Despoina Perrea; Dimitrios Iliopoulos; John Barbetseas; Vasilios Papademetriou
Journal:  J Hum Hypertens       Date:  2019-01-15       Impact factor: 3.012

Review 10.  Effects of Antihypertensive Therapy on Blood Pressure Variability.

Authors:  Kazuo Eguchi
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.